Enanta Pharmaceuticals Stock (NASDAQ:ENTA)
Previous Close
$5.86
52W Range
$5.70 - $17.80
50D Avg
$9.86
200D Avg
$12.48
Market Cap
$133.10M
Avg Vol (3M)
$268.34K
Beta
0.57
Div Yield
-
ENTA Company Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
ENTA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. |
| MRUS | Merus N.V. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| IKNA | Ikena Oncology, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| INBX | Inhibrx Biosciences, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |